Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EBIT: 2018-2024

Historic EBIT for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$63.3 million.

  • Silence Therapeutics' EBIT rose 12.51% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 1.45%. This contributed to the annual value of -$63.3 million for FY2024, which is 1.65% up from last year.
  • Per Silence Therapeutics' latest filing, its EBIT stood at -$63.3 million for FY2024, which was up 1.65% from -$64.4 million recorded in FY2023.
  • Silence Therapeutics' 5-year EBIT high stood at -$46.0 million for FY2020, and its period low was -$64.4 million during FY2023.
  • Moreover, its 3-year median value for EBIT was -$63.3 million (2024), whereas its average is -$62.9 million.
  • Per our database at Business Quant, Silence Therapeutics' EBIT plummeted by 58.58% in 2020 and then rose by 3.16% in 2022.
  • Silence Therapeutics' EBIT (MRY) stood at -$46.0 million in 2020, then crashed by 36.93% to -$63.0 million in 2021, then increased by 3.16% to -$61.0 million in 2022, then decreased by 5.48% to -$64.4 million in 2023, then rose by 1.65% to -$63.3 million in 2024.
  • Its EBIT stands at -$63.3 million for FY2024, versus -$64.4 million for FY2023 and -$61.0 million for FY2022.